Novartis | NOVN - Current Assets


Novartis reported $26.61B in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
AbbVie USD 33.53B 4.47B Mar/2026
Alcon AG USD 6.62B 171M Mar/2026
Almirall EUR 713.98M 69K Dec/2025
Amgen USD 31.48B 2.42B Mar/2026
AstraZeneca USD 29.61B 890M Mar/2026
Autolus Therapeutics Ltd USD 368.84M 67.08M Mar/2026
Bayer EUR 35.3B 2.39B Mar/2026
Biogen USD 9.19B 216.3M Mar/2026
Bristol-Myers Squibb USD 27.21B 2.18B Mar/2026
Eli Lilly USD 54.84B 794M Mar/2026
Fresenius EUR 11.03B 1.03B Dec/2025
Fresenius Medical Care EUR 8.11B 209.55M Mar/2026
Genmab DKK 2.88B 1.59B Dec/2025
Gilead Sciences USD 18.64B 1.25B Mar/2026
GlaxoSmithKline GBP 17.76B 251M Mar/2026
GRIFOLS EUR 5.25B 180M Mar/2026
Hikma Pharmaceutical USD 2.64B 86M Dec/2025
J&J USD 59.17B 3.55B Mar/2026
Lakefront Biotherapeutics EUR 3.06B 18.72M Mar/2026
Lonza CHF 8B 3.41B Dec/2025
Merck EUR 14.16B 932M Mar/2026
Merck USD 35.02B 8.5B Mar/2026
Novartis USD 26.61B 3.85B Mar/2026
Novartis USD 30.46B 2.26B Dec/2025
Novo Nordisk DKK 177.32B 4.86B Mar/2026
Orion EUR 1.41B 66.8M Mar/2026
Pfizer USD 42.82B 76M Mar/2026
Philips EUR 9.78B 148M Mar/2026
Recordati EUR 1.73B 50.28M Mar/2026
Regeneron Pharmaceuticals USD 18.21B 187.3M Mar/2026
Roche Holding CHF 38.73B 3.03B Dec/2025
Sanofi EUR 30.16B 789M Mar/2026
UCB EUR 6.05B 733M Dec/2025